Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

New circulating tumor cell technology could advance personalized medicine in prostate cancer.

Miller S.

Nanomedicine (Lond). 2013 May;8(5):683-4. doi: 10.2217/nnm.13.78. No abstract available.

2.

Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter.

Attard G, Crespo M, Lim AC, Pope L, Zivi A, de Bono JS.

Clin Cancer Res. 2011 May 1;17(9):3048-9; author reply 3050. doi: 10.1158/1078-0432.CCR-10-3234. No abstract available.

3.

Molecular detection of circulating prostate cells in cancer II: Comparison of prostate epithelial cells isolation procedures.

Berteau P, Dumas F, Gala JL, Eschwège P, Lacour B, Philippe M, Loric S.

Clin Chem. 1998 Aug;44(8 Pt 1):1750-3. No abstract available.

4.

Making personalized prostate cancer medicine a reality: challenges and opportunities in the re-establishment of gold standards.

Farooqi AA, Butt G, Yousaf G, Qadir MI, Shaukat U, Mansoor Q, Awan M, Bhatti S, Begum A.

Pak J Pharm Sci. 2013 Jul;26(4):831-40. Review.

PMID:
23811467
5.

Circulating endothelial cells as biomarkers of prostate cancer.

Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM.

Nat Clin Pract Urol. 2008 Aug;5(8):445-54. doi: 10.1038/ncpuro1188. Review.

PMID:
18682720
6.

Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.

Chan F, Goodman O, Fink L, Vogelzang NJ, Pomerantz D, Khoury JD.

Arch Pathol Lab Med. 2010 Jan;134(1):120-3. doi: 10.1043/2009-0022-CRR1.1.

PMID:
20073615
7.

In vitro technique for isolating prostatic cells from blood.

Harty JI, Blicblum S, Amin M.

J Surg Res. 1979 Apr;26(4):411-6. No abstract available.

PMID:
431059
8.

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.

Saad F, Pantel K.

Future Oncol. 2012 Mar;8(3):321-31. doi: 10.2217/fon.12.3. Review.

PMID:
22409467
9.

Biomarkers for the diagnosis of new and recurrent prostate cancer.

Sardana G, Diamandis EP.

Biomark Med. 2012 Oct;6(5):587-96. doi: 10.2217/bmm.12.72. Review.

PMID:
23075237
11.

The use of flow cytometry and RT-PCR in the detection of circulating PSA-positive cells in prostate cancer.

Fadlon EJ, Hamdy FC.

Methods Mol Biol. 1998;92:215-25. No abstract available.

PMID:
9664517
12.

Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.

Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE.

Prostate. 2012 Oct 1;72(14):1532-41. doi: 10.1002/pros.22508. Review.

13.

[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer].

Kippersund JT, Haukeland B, Lilleeng BF, Daehlin L, Haukaas S, Høisaeter PA, Ogreid D.

Tidsskr Nor Laegeforen. 1995 Nov 30;115(29):3612-5. Norwegian.

PMID:
8539714
14.

Combined detection of cancer cells and a tumor biomarker using an immunomagnetic sensor for the improvement of prostate-cancer diagnosis.

Yang HW, Lin CW, Hua MY, Liao SS, Chen YT, Chen HC, Weng WH, Chuang CK, Pang ST, Ma CC.

Adv Mater. 2014 Jun 11;26(22):3662-6. doi: 10.1002/adma.201305842. No abstract available.

PMID:
24648414
15.

Detection and isolation of prostate cancer cells from peripheral blood and bone marrow.

Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL.

Urology. 2003 Feb;61(2):277-81.

PMID:
12597930
16.

Circulating fibroblast-like cells in men with metastatic prostate cancer.

Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH.

Prostate. 2013 Jan;73(2):176-81. doi: 10.1002/pros.22553.

17.

Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy.

Mitra R, Chao O, Urasaki Y, Goodman OB, Le TT.

BMC Cancer. 2012 Nov 21;12:540. doi: 10.1186/1471-2407-12-540.

18.

Prostate cancer: Probing progression in circulating tumour cells.

Phillips R.

Nat Rev Urol. 2014 Sep;11(9):486. doi: 10.1038/nrurol.2014.208. No abstract available.

PMID:
25112853
19.

A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.

Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, Olivares R, Dueñas R.

Arch Esp Urol. 2013 May;66(4):335-41. English, Spanish.

PMID:
23676536
20.

High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing.

Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, OuYang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM.

Adv Mater. 2013 Jun 4;25(21):2897-902. doi: 10.1002/adma.201205237.

Items per page

Supplemental Content

Support Center